Flow-cytometric screening of aggregation-inhibitors using a fluorescence-assisted intracellular method

Biotechnology Journal

Volumn 12, Issue 1, 2017, Pages

  Lindberg, Hanna ^a   Sandersjöö, Lisa ^a   Meister, Sebastian W ^a   Uhlén, Mathias ^a   Löfblom, John ^a   Ståhl, Stefan ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Affibody molecules; Aggregation inhibitor; Amyloid beta; Combinatorial protein engineering; Intracellular selection system

Indexed keywords

CELLS; CYTOLOGY; DIAGNOSIS; GLYCOPROTEINS; MOLECULES; NEURODEGENERATIVE DISEASES; PEPTIDES;

AFFIBODY MOLECULES; AGGREGATION INHIBITORS; AMYLOID BETAS; PROTEIN ENGINEERING; SELECTION SYSTEMS;

FLUORESCENCE;

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTITHROMBOCYTIC AGENT; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; BACTERIAL STRAIN; CELL SCREENING; COMBINATORIAL LIBRARY; CONTROLLED STUDY; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; CHEMISTRY; FLUORESCENCE; GENE VECTOR; GENETICS; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; RECOMBINANT PROTEINS;

EID: 85006293410     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201600364     Document Type: Article

References (24)

1. Krishnamurthy, P. K., Sigurdsson, E. M., Therapeutic applications of antibodies – antibodies in non-infectious neurodegenerative diseases. N. Biotechnol. 2001, 28, 511–517.
2. Wisniewski, T., Goni, F., Immunotherapeutic approaches for Alzheimer's disease. Neuron 2015, 85, 1162–1176.
3. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F. et al., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416, 507–511.
4. Haass, C., Selkoe, D. J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8, 101–112.
5. Wisniewski, T., Goni, F., Immunotherapy for Alzheimer's disease. Biochem. Pharmacol. 2014, 88, 499–507.
6. Lofblom, J., Bacterial display in combinatorial protein engineering. Biotechnol. J. 2011, 6, 1115–1129.
7. Lindberg, H., Härd, T., Löfblom, L., Ståhl, S., A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity. Biotechnol. J. 2015, 10, 1707–1718.
8. Esler, W. P., Stimson, E. R., Ghilardi, J. R., Felix, A. M. et al., A deposition inhibitor screen using synthetic amyloid. Nat. Biotechnol. 1997, 15, 258–263.
9. Blanchard, B. J., Chen, A., Rozeboom, L. M., Stafford, K. A. et al., Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 14326–14332.
10. Saunders, J. C., Young, L. M., Mahood, R. A., Jackson, M. P. et al., An in vivo platform for identifying inhibitors of protein aggregation. Nat. Chem. Biol. 2016, 12, 94–101.
11. Zhao, J., Nelson, T. J., Vu, Q., Truong, T., Stains, C. I., Self-assembling NanoLuc luciferase fragments as probes for protein aggregation in living cells. ACS Chem. Biol. 2016, 11, 132–138.
12. Wurth, C., Guimard, N. K., Hecht, M. H., Mutations that reduce aggregation of the Alzheimer's Aβ42 peptide: An unbiased search for the sequence determinants of Aβ amyloidogenesis. J. Mol. Biol. 2002, 319, 1279–1290.
13. Kim, W., Kim, Y., Min, J., Kim, D. J. et al., A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol. 2006, 1, 461–469.
14. Baine, M., Georgie, D. S., Shiferraw, E. Z., Nguyen, T. P. et al., Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries. J. Pept. Sci. 2009, 15, 499–503.
15. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J. et al., Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584, 2670–2680.
16. Hoyer, W., Gronwall, C., Jonsson, A., Stahl, S., Hard, T., Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. USA 2008, 105, 5099–5104.
17. Luheshi, L. M., Hoyer, W., de Barros, T. P., van Dijk Hard, I. et al., Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 2010, 8, e1000334.
18. Gronwall, C., Jonsson, A., Lindstrom, S., Gunneriusson, E. et al., Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128, 162–183.
19. Mirecka, E. A., Shaykhalishahi, H., Gauhar, A., Akgül, Ş. et al., Sequestration of a b-hairpin enables control of a-synuclein aggregation. Angew. Chem. Int. Ed. 2014, 53, 4227–4230.
20. Kostallas, G., Samuelson, P., Novel fluorescence-assisted whole-cell assay for engineering and characterization of proteases and their substrates. Appl. Environ. Microbiol. 2010, 76, 7500–7508.
21. Lyakhov, I., Zielinski, R., Kuban, M., Kramer-Marek, G. et al., HER2- and EGFR-specific affiprobes: Novel recombinant optical probes for cell imaging. ChemBioChem 2010, 11, 345–350.
22. Guzman, L. M., Belin, D., Carson, M. J., Beckwith, J., Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 1995, 177, 4121–4130.
23. Lindberg, H., Johansson, A., Hard, T., Stahl, S., Lofblom, J., Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid-beta peptide. Biotechnol. J. 2013, 8, 139–145.
24. Gauhar, A., Shaykhalishahi, H., Gremer, L., Mirecka, E. A., Hoyer, W., Impact of subunit linkages in an engineered homodimeric binding protein to alpha-synuclein. Protein Eng. Des. Sel. 2014, 27, 473–479.